Vistagen Therapeutics (VTGN) Convertible Debt (2011 - 2015)
Vistagen Therapeutics (VTGN) posted Convertible Debt of $549500.0 for Q1 2015, down 88.57% sequentially from $4.8 million in Q1 2011.
Vistagen Therapeutics (VTGN) Convertible Debt (2011 - 2015) Analysis & Trends
Vistagen Therapeutics has reported Convertible Debt for 2 years, with the latest figure at $549500.0 in Q1 2015.
- Quarterly Convertible Debt changed N/A year-over-year to $549500.0 in Q1 2015, while the trailing twelve-month figure through Mar 2015 was $549500.0 (changed N/A YoY) and the FY2015 annual result came in at $549500.0, changed N/A from the prior year.
- Convertible Debt declined to $549500.0 in Q1 2015 per VTGN's latest filing, from $4.8 million in the prior quarter.
- Over five years, Convertible Debt peaked at $4.8 million in Q1 2011 and troughed at $549500.0 in Q1 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | 549,500.00 |
| Mar 31, 2011 | 4.81 Mn |